The $7 Billion Men's Sexual Health Telehealth Market Nobody Is Building

---

title: "The $7 Billion Men's Sexual Health Telehealth Market Nobody Is Building" slug: "mens-sexual-health-telehealth-market-opportunity" meta_title: "The $7B Men's Sexual Health Telehealth Market | Rimo Health" meta_description: "Erectile dysfunction and sexual wellness telehealth is a $7B opportunity. Learn the medications, margins, and model that actually work." tags: ["mens-health-telehealth", "erectile-dysfunction-telehealth", "sexual-wellness-business", "telehealth-business-opportunity", "ed-medication-business"] cover_image_query: "men's health consultation" excerpt: "The men's sexual health telehealth market is projected to hit $7B by 2028. Here's exactly what it takes to build a profitable brand in this space."

The first time I saw a telehealth brand crack $100K in monthly revenue, it wasn't selling weight loss shots. It wasn't pushing testosterone creams. It was selling sildenafil — generic Viagra — to men who didn't want to walk into a pharmacy and ask for it.

That was 2019. Today, the market is 10x bigger, the margins are tighter, and the competition is fiercer. But the opportunity? It's still massive — and most founders are sleeping on it.

If you're evaluating which telehealth vertical to build in, men's sexual health deserves a hard look. Here's why.

The Market Size Isn't Just Big — It's Undertapped

Let's get specific. The global erectile dysfunction (ED) market is projected to reach $7.3 billion by 2028, growing at roughly 8% annually. In the US alone, it's a $3.5 billion market — and only about 25% of men with ED actually seek treatment.

That's the gap: 75% of the addressable market isn't being served. Not because the medication doesn't work. Not because the demand isn't there. Because the existing options suck.

Men don't want to:

• Sit in a waiting room next to their neighbor
• Have a face-to-face conversation about their performance with a doctor they've never met
• Pick up a paper bag from the local pharmacy counter
• Pay $50 per pill at retail

Telehealth solves every single one of those friction points. And the brands doing it right are generating $50K-$150K per month within their first 12 months.

Who Are These Patients?

The core demographic for men's sexual health telehealth skews 35-65, with the highest conversion rates in the 40-55 age bracket. These are men who:

• Have disposable income ($75K+ household income)
• Are comfortable buying online (Amazon Prime mindset)
• Value privacy above all else
• Are already spending money on supplements, gym memberships, or "male enhancement" products

Here's what most founders get wrong: they think the patient is a 65-year-old with severe ED who's tried everything. That's maybe 10% of the market.

The real opportunity is the 40-year-old who's noticed a change — maybe after stress, weight gain, or just aging — and wants a low-friction, discreet solution. He's not embarrassed enough to see a doctor in person, but he's also not going to make an appointment either. He's going to Google "ED medication online" and click the first ad that looks legitimate.

The Medications That Actually Move

This is where a lot of telehealth founders lose money. They pick the wrong pharmacy partners, stock the wrong formulations, or price themselves out of the market.

Here's what works:

Sildenafil (Generic Viagra)

• Cost: $1.50-$3.00 per dose (compounded or generic)
• Retail: $15-$25 per dose at traditional pharmacies
• Telehealth price: $30-$60 per month (subscription)
• Margin: 70-85%

Sildenafil is the volume driver. It's what most men start with. It's well-known (patients ask for it by name), it's effective, and it's cheap to source. If you're only going to carry one medication, this should be it.

Tadalafil (Generic Cialis)

• Cost: $2.00-$4.00 per dose
• Retail: $20-$35 per dose
• Telehealth price: $40-$70 per month
• Margin: 65-80%

Tadalafil is the upsell. It lasts 36 hours (vs. sildenafil's 4-6 hours), which appeals to men who want spontaneity. It's also slightly more expensive to source, but patients are willing to pay a premium.

Combination Therapies

The highest LTV patients — the ones who stay for 12+ months — are usually on combination therapies: sildenafil for "as-needed" use plus a daily low-dose tadalafil regimen. Some brands also add testosterone screening and supplementation, which increases the average order value by 40-60%.

Compounded vs. Brand-Name: The Economics

Here's the part most founders overcomplicate.

Brand-name medications (Viagra, Cialis) carry massive markup potential — but only if you can command a premium price. Most patients know these drugs exist and expect to pay less online. The margin on brand-name sildenafil at $30/pill is theoretically high, but you're competing with pharmacies selling generic for $3.

Compounded medications are where the real margins live — especially for customized dosages, unique formulations (troches, sublingual tablets, topical gels), or combination products that don't exist in commercial form.

But there's a catch: you need a 503A compounding pharmacy that's licensed in the patient's state. Not all pharmacies can ship everywhere. And the regulatory landscape for compounding has tightened significantly since the 2023 FDA crackdowns.

The smart play? Start with generic FDA-approved medications from a 503B outsourcing facility (like the ones Rimo pre-integrates with) to build volume and prove the model. Then add compounded formulations as you scale and your pharmacy relationships mature.

The Patient Journey: What Actually Converts

Most telehealth brands lose 60-70% of visitors at the intake form. Here's what a high-converting patient journey looks like:

1. Landing page: Clean, clinical, trustworthy. Not "bro-science." No before/after photos of guys with six-pack abs. Think: medical professionalism meets modern DTC brand.

2. Quiz/intake: 5-7 questions max. Age, symptoms, medical history, current medications. Don't ask for their social security number or insurance info upfront. You're not billing insurance anyway.

3. Provider consultation: 10-15 minute video or asynchronous text. The provider reviews the intake, approves the prescription, and moves the patient to checkout. This is where most brands lose people — keep it frictionless.

4. Pharmacy fulfillment: Medication ships within 24-48 hours. Discrete packaging. Patient receives tracking. This is where you build trust.

5. Refill/retention: This is where the money is. The average male sexual health patient stays on medication for 14-18 months. Your subscription model should incentivize auto-refill: $30/month with free shipping vs. $45 one-time.

Pricing Models That Work

The three pricing tiers you're likely to see in the market:

The sweet spot for most new brands is the entry tier at $35/month — it's low enough to convert, high enough to profit, and sets you up for upsells later.

The Regulatory Reality (Plain English)

I won't bury you in legalese, but here's what you need to know:

• Telemedicine rules: Most states allow remote prescribing of ED medications — but some require an initial in-person visit or video consultation with audio and visual. Check your state. (Rimo's provider network covers all 50 states and handles this automatically.)

• Controlled substances: Sildenafil and tadalafil are not controlled substances under federal law. This is a massive advantage over testosterone or weight loss medications, which face stricter prescribing limits.

• LegitScript certification: Most payment processors and advertising platforms (Google, Meta) require LegitScript certification before you'll be approved to run ads for prescription medications. This is non-negotiable if you want to scale with paid acquisition.

• HIPAA compliance: Your platform, your provider documentation, and your pharmacy relationships all need to be HIPAA-compliant. If you're using a white-label solution, make sure it's SOC 2 certified and HIPAA-compliant out of the box.

Competition: Who's Winning and Who's Losing

The men's sexual health telehealth space has a few dominant players (Roman, Hims, BlueChew) and a ton of small, fragmented brands that are barely profitable.

Here's what separates the winners:

• Brand positioning: The big players market to everyone. The winners niche down — "ED for men over 40," "natural performance optimization," "discreet daily support."

• Acquisition cost: Hims spends $150+ to acquire a customer. A lean, well-optimized D2C brand can get that down to $40-$80 through organic content, SEO, and strategic influencer partnerships.

• Retention: The average brand loses 40% of patients after month 3. Brands that implement auto-refill programs, quarterly check-ins, and personalized dosing adjustments see retention rates above 65%.

• Margins: The brands making real money aren't just selling pills. They're selling memberships — $49/month includes medication, provider access, and quarterly health assessments. That's $588/year per patient, with 80%+ margin.

How to Actually Build This (The Short Version)

If you're ready to move from "interesting opportunity" to "building a brand," here's your roadmap:

1. Pick your niche: Don't try to be everything to everyone. "Men's sexual health" is a category. "ED for active men over 40" is a position.

2. Secure your pharmacy partners: You need a 503B that can ship to all 50 states, offers competitive pricing on sildenafil and tadalafil, and handles discrete fulfillment. (Rimo pre-integrates with pharmacies that check all these boxes.)

3. Build your clinical layer: You need licensed providers in every state where you operate. You also need malpractice insurance, clinical protocols, and documentation standards. This is where most first-time founders stall — the provider recruitment and compliance work is tedious. Rimo's provider network handles this for you.

4. Launch with one medication: Sildenafil. 10mg or 20mg. Subscription only. Get 100 patients. Prove the unit economics. Then expand.

5. Optimize for retention first: Your second 100 patients should cost less to acquire than your first 100. Your third 100 should cost less than your second. If you're still paying $100/CAC at patient 300, something's broken in your funnel.

The Bottom Line

Men's sexual health telehealth isn't the newest trend. It's not the flashiest vertical. But it's one of the most profitable, least saturated, and most defensible opportunities in D2C telehealth today.

The market is large ($7B+), the patients are high-LTV (12-24 months), the medications are cheap to source, the regulatory burden is lighter than weight loss or testosterone, and the competition is fragmented enough that a well-executed brand can capture meaningful share.

The brands that will win in this space aren't the ones with the biggest ad budgets. They're the ones who treat this like a real business — with disciplined unit economics, strong retention, and a brand that men actually trust.

If you've been waiting for a sign to build in men's health, this is it.

---

Ready to launch your men's health telehealth brand? Rimo handles the pharmacy integrations, provider network, HIPAA compliance, and payment processing — so you can focus on patient acquisition and brand growth. Get a platform walkthrough at rimohealth.com.